Selenium and prostate cancer: analysis of individual participant data from fifteen prospective studies
Naomi E. Allen
(1, 2)
,
Ruth C. Travis
(3)
,
Paul N. Appleby
(3)
,
Demetrius Albanes
(4)
,
Matt J. Barnett
(5)
,
Amanda Black
(4)
,
H. Bas Bueno-De-Mesquita
(6, 7, 8, 9)
,
Mélanie Deschasaux
(10, 11)
,
Pilar Galan Hercberg
(10, 11)
,
Gary E. Goodman
(5)
,
Phyllis J. Goodman
(12)
,
Marc J. Gunter
(13)
,
Markku Heliovaara
(14)
,
Kathy J. Helzlsouer
(15)
,
Brian E. Henderson
(16)
,
Serge Hercberg
(10, 11)
,
Paul Knekt
(14)
,
Laurence N. Kolonel
(17)
,
Christina Lasheras
(18)
,
Jakob Linseisen
(19, 20)
,
E. Jeffrey Metter
(21)
,
Marian L. Neuhouser
(5)
,
Anja Olsen
(22)
,
Valeria Pala
(23)
,
Elizabeth A. Platz
(24)
,
Harri Rissanen
(14)
,
Mary E. Reid
(25)
,
Jeannette M. Schenk
(24, 26)
,
Meir J. Stampfer
(24, 27)
,
Par Stattin
(28)
,
Catherine M. Tangen
(29, 30)
,
Mathilde Touvier
(10, 11)
,
Antonia Trichopoulou
(31)
,
Piet A. van den Brandt
(32)
,
Timothy J. Key
(3)
1
Nuffield Department of Population Health - Clinical Trial Service Unit
2 Nuffield Department of Population Health - Epidemiological Studies Unit
3 Nuffield Department of Population Health - Cancer Epidemiology Unit
4 Division of Cancer Epidemiology and Genetics
5 Division of Public Health Science
6 Faculty of Medicine - Department of Social and Preventive Medicine
7 School of Public Health - Departmen of Epidemiology and Biostatistics
8 Department of Gastroenterology and Hepatology
9 Department for Determinants of Chronic Diseases
10 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
11 USPC - Université Sorbonne Paris Cité
12 SWOG Southwest Oncology Group
13 School of Public Health - Department of Epidemiology and Biostatistics
14 National Institute for Health and Welfare [Helsinki]
15 Prevention and Research Center
16 Keck School of Medicine [Los Angeles]
17 Cancer Center
18 Faculty of Medicine - Department of Functional Biology
19 Division of Cancer Epidemiology
20 Institute of Epidemiology II
21 Health Science Center - Department of Neurology - Intramural Research Program - National Institute of AgingUSA
22 Danish Cancer Society Research Center
23 Epidemiology and Prevention Unit
24 Department of Epidemiology
25 RPCI - Roswell Park Cancer Institute [Buffalo]
26 Cancer Prevention Program
27 Brigham and Women's Institute - Channing Division of Network Medicine
28 Department of Surgery and Perioperative Sciences - Urology and Andrology
29 Department of Biostatistics [Oslo]
30 SWOG Southwest Oncology Group
31 Hellenic Health Foundation
32 GROW School for Oncology and Developmental Biology - Department of Epidemiology
2 Nuffield Department of Population Health - Epidemiological Studies Unit
3 Nuffield Department of Population Health - Cancer Epidemiology Unit
4 Division of Cancer Epidemiology and Genetics
5 Division of Public Health Science
6 Faculty of Medicine - Department of Social and Preventive Medicine
7 School of Public Health - Departmen of Epidemiology and Biostatistics
8 Department of Gastroenterology and Hepatology
9 Department for Determinants of Chronic Diseases
10 CRESS (U1153 / UMR_A_1125 / UMR_S_1153) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
11 USPC - Université Sorbonne Paris Cité
12 SWOG Southwest Oncology Group
13 School of Public Health - Department of Epidemiology and Biostatistics
14 National Institute for Health and Welfare [Helsinki]
15 Prevention and Research Center
16 Keck School of Medicine [Los Angeles]
17 Cancer Center
18 Faculty of Medicine - Department of Functional Biology
19 Division of Cancer Epidemiology
20 Institute of Epidemiology II
21 Health Science Center - Department of Neurology - Intramural Research Program - National Institute of AgingUSA
22 Danish Cancer Society Research Center
23 Epidemiology and Prevention Unit
24 Department of Epidemiology
25 RPCI - Roswell Park Cancer Institute [Buffalo]
26 Cancer Prevention Program
27 Brigham and Women's Institute - Channing Division of Network Medicine
28 Department of Surgery and Perioperative Sciences - Urology and Andrology
29 Department of Biostatistics [Oslo]
30 SWOG Southwest Oncology Group
31 Hellenic Health Foundation
32 GROW School for Oncology and Developmental Biology - Department of Epidemiology
Mélanie Deschasaux
- Fonction : Auteur
- PersonId : 183648
- IdHAL : melanie-deschasaux
- ORCID : 0000-0002-3359-420X
- IdRef : 236007823
Serge Hercberg
- Fonction : Auteur
- PersonId : 1136672
- ORCID : 0000-0002-3168-1350
- IdRef : 02858709X
Anja Olsen
- Fonction : Auteur
- PersonId : 757529
- ORCID : 0000-0003-4788-503X
Valeria Pala
- Fonction : Auteur
- PersonId : 764917
- ORCID : 0000-0001-5438-970X
Mathilde Touvier
- Fonction : Auteur
- PersonId : 1136541
Timothy J. Key
- Fonction : Auteur
- PersonId : 925891
Résumé
Background: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. Methods: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided. Results: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, P-heterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, P-trend <.001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, P-heterogeneity =.08). Conclusions: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-termselenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.